We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks, presumably I've missed the record date then.
Sportstrader kindly done for for you...cheers..
Imutex
- FLU-v is a phase III ready universal flu vaccine. Could be worlds first. Expecting FDA news soon regarding that.
- AGS-v is a phase II ready mosquito saliva borne diseases including Zika, malaria and Dengue which effects 700 million people a year, deaths 1 million.
-FLU-v, AGS-v and immune modulator will be put into the Imutex newco which will be listed on NASDAQ for a 1 for 1 share.
- Funding for Flu-v will cost around 100million, so getting 3rd party funding, likely the Chinese who have been in talks for past 2 years.
- Will be listed on NASDAQ for 1:1 share, in approx 2-3 months.
Don't forget to join the telegram research / chat group:
https://t.
me/joinchat/HkgNOBsQH1ZuELB5k9fr2g
just remove the spaces
@moniman could you expand on that or point me in the right direction please.
Yep.
Bonus ball :)
And that doesn't include our free shares in Imutex.
Yep.
Good whichever way you calc.
A point of correction on SP to Mcap. Don't forget that come 12th June or thereabouts, we should be registering 663,860,098 ordinary shares. This would mean a potential £400 Mcap, translates to an SP of circa 60p. So about 4x now and yet obviously sill a fantastic price if achieved.
I was basing my calc on actual sales leading to confirmed cap.
But yes, it's likely market will drive price well ahead of my timeline.
It's speculative at moment until we have sales data breakdown on antibody tests.
It's upwards, whichever way you look at it :)
400millon market cap would be about 75.0
Thats 5x from here
further contracts nailed plus sales data breakdown of tests will be guide.
bit too early yet.
plenty of time :)
no doubt there'll be lots of buying pushing mkt cap upwards ahead of above.
I think It will be now, over next few weeks or months (IMO), as we have II's on board? As mentioned, thats is my opinion, DYOR
chasrutledge
Cathal targeting 400 million mkt cap by December 2020 IMO.
or, reduced mkt cap and dividend payout.
Just my opinion.
He also mentioned that we are close to 100m market cap and can get a lot more. Plus he said 'exit strategy is to focus people's minds and we could have a business worth Many 100s of millions, so why would we give that away.' (Check time 28 minutes in.)
https://youtu.be/BBjvwtopf0I
Today's twitter comment from Open Orphan promoting the expansion to a second machine [upon hitting max on first machine] is the very opposite of Cathal's recent 'go easy' comment. Now, there's no holding back.
How can potential new investors ignore this appetizing news feast??